ArticleCureus2025
The Role of Antipsychotic Medications on Metabolic and Hematological Parameters.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of TNF and TLR2 genes with blood parameter levels in Mexican patients with schizophrenia.BMC psychiatry · 2025Article
- Pharmacological modulation of the gut-brain axis: psychobiotics in focus for depression therapy.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsychiatric disorders, including schizophrenia, bipolar disorder, and drug-induced psychosis, are associated with significant biochemical and hematological alterations. Antipsychotic medications, particularly second-generation antipsychotics, have been implicated in metabolic disturbances, hormonal imbalances, and hematological changes.
objectiveThis study aimed to evaluate the impact of psychiatric disorders and antipsychotic medications on metabolic and hematological parameters, identifying potential risks associated with long-term treatment.
methodsA prospective hospital-based study was conducted on 80 psychiatric patients and 15 healthy controls. Biochemical markers, such as fasting blood sugar (FBS), glycated hemoglobin (HbA1c), lipid profile, C-reactive protein (CRP), thyroid-stimulating hormone (TSH), and prolactin, were assessed. Hematological parameters, including hemoglobin (Hb), white blood cell (WBC) count, platelet count, and serum albumin, were analyzed. Statistical comparisons were conducted using IBM SPSS Statistics for Windows, Version 23.0 (Released 2015; IBM Corp., Armonk, NY, United States), with significance set at p < 0.05.
resultsPsychiatric patients showed higher levels of HbA1c, CRP, low-density lipoprotein (LDL), and prolactin compared to controls. Second-generation antipsychotics (SGAs) were more strongly associated with metabolic dysregulation than first-generation antipsychotics (FGAs). Hematological alterations included lower hemoglobin and higher platelet count in psychiatric patients.
conclusionPsychiatric disorders and antipsychotic therapy are associated with significant metabolic and hematological changes, requiring regular monitoring and preventive strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.